GENFIT Celebrates a Major Milestone with Iqirvo® Approval
GENFIT, a biopharmaceutical firm, has reached an important milestone with the European Commission's conditional approval of Iqirvo® (elafibranor) 80mg tablets. This approval is specifically aimed at treating Primary Biliary Cholangitis (PBC), whether in combination with ursodeoxycholic acid (UDCA) or on its own for those intolerant to UDCA. This development is a promising advancement in managing a condition affecting many people throughout Europe.
Insights from the CEO on the Approval
Pascal Prigent, the CEO of GENFIT, shared his enthusiasm about the approval, stating, "The approval of Iqirvo in the EU is another landmark moment for GENFIT. It validates our scientific and clinical capabilities and highlights our journey in bringing Iqirvo from its initial discovery to this point." He emphasized that Iqirvo now represents a crucial new treatment alternative for patients dealing with PBC.
Financial Outcome of Iqirvo's Approval
The expected milestone payment of €26.5 million following Iqirvo's pricing and reimbursement approval indicates GENFIT's strong position to enhance its pipeline further. This is particularly relevant for severe liver diseases, especially those with significant unmet medical needs such as Acute On-Chronic Liver Failure.
Background Information on Elafibranor
Elafibranor stands out as a 'first-in-class' medication specifically developed to address PBC. Since June 2024, it has been marketed in the U.S. by Ipsen under the Iqirvo name. GENFIT created elafibranor from the ground up, navigating challenging clinical studies that culminated in a successful 52-week Phase 3 clinical trial. In 2021, GENFIT granted exclusive worldwide rights to Ipsen, with exceptions for territories like China and Hong Kong.
Significance for Liver Disease Patients
This approval carries special importance for those suffering from Primary Biliary Cholangitis, a chronic autoimmune condition that can lead to serious liver issues if untreated. With Iqirvo offered as an alternative treatment, patients now have more effective options for managing their condition.
GENFIT's Mission Beyond Iqirvo
GENFIT is dedicated to improving the lives of patients with rare and severe liver conditions. With a rich history of innovation spanning two decades, the company is in a strong position to lead in liver disease research and development. Their portfolio includes a variety of research stages and multiple promising assets aimed at addressing unmet medical needs.
A Snapshot of GENFIT's R&D Portfolio
GENFIT’s goals extend beyond just Iqirvo’s approval. The company is actively pursuing research initiatives targeting Acute-on-Chronic Liver Failure (ACLF), with five assets currently in development. These include VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE, each utilizing unique mechanisms of action. They are also investigating treatments for other serious conditions such as cholangiocarcinoma, urea cycle disorder, and organic acidemia.
Conclusion and Future Outlook
With the recent conditional approval of Iqirvo by the EU, GENFIT is poised for ongoing advancements in liver disease treatment. This milestone not only highlights the company’s commitment to patient care but also places it on a path toward future innovations. As GENFIT progresses in developing its pipeline and exploring new therapeutic options, the outlook looks hopeful for both the company and those affected by liver diseases.
Frequently Asked Questions
What is Iqirvo® used for?
Iqirvo® is approved for the treatment of Primary Biliary Cholangitis (PBC) in adults, either in combination with UDCA or as a solo therapy.
What are the implications of the EU approval for patients?
The EU's approval of Iqirvo® opens up new treatment options for patients, which may help improve their management of PBC.
Who developed elafibranor?
Elafibranor was developed by GENFIT and is marketed in the United States by Ipsen under the Iqirvo® brand.
What is GENFIT's focus aside from PBC?
GENFIT is also working on treatments for other severe liver conditions, including Acute On-Chronic Liver Failure as well as various rare liver diseases.
How can I find more information about GENFIT's developments?
You can find further updates and details on GENFIT's official website, including their public assessments on drug approvals and research initiatives.
